Login to Your Account



Clinic Roundup


Monday, August 6, 2012
• Healthpoint Biotherapeutics, of Fort Worth, Texas, said that the results for its Phase IIb trial investigating the efficacy of HP802-247 in venous leg ulcers are published in The Lancet.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription